Ann: US FDA & IRB approves start of ph2b head & neck cancer trial, page-8

Given the immutep "step change" process was evolving when the fast track trial status was granted for Head and neck
cancer and also the scaleup of production occuring almost, if not together it seems Immutep considers the new PHIIb
trial may be the quickest avenue to receive commercial approval for manufacture of "EFTI"...
The cash is there now to get this moving without having one eye on the bank balance and so a degree
of freedom for decisions....In the concept of business the decision to engage Merck for supply only
collaboration agreements re keytruda and efti could well be a company maker giving immutep has sole
control should the trial be successful and approval ensues....
We are in a good place.......

p.s I wonder whether fast track has been applied for for NSCLC?...